On May 24, 2024 Foundation Medicine, Inc., reported that 22 new pieces of research from its robust oncology diagnostics portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from May 31 to June 4 in Chicago (Press release, Foundation Medicine, MAY 24, 2024, View Source [SID1234643703]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Emerging Applications of Liquid Biopsy Using FoundationOneLiquid CDx and FoundationOneTracker
Utility of circulating tumor DNA (ctDNA) to inform treatment of patients with metastatic breast cancer (Abstract #1042)
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO (Abstract #TPS3644)
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (Abstract #5020)
Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC) (Abstract #5085)
BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy (Abstract #5056)
Utility of CGP in Earlier Stages of Disease, Rare Cancers, and Using RNA Sequencing
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early-stage lung cancer (LEADER) screening trial (Abstract #8068)
Impact of alterations in tumor suppressor genes (TSG-alt) on survival outcomes in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) receiving androgen deprivation therapy (ADT) with androgen receptor pathway inhibition (ARPI) or docetaxel (Abstract #5091)
On the right TRACK: Providing comprehensive genomic profiling (CGP) and molecular tumor board (MTB) for patients (pts) with rare cancers (Abstract #3127)
New soft tissue sarcoma (STS) transcriptomic clusters to unveil STS subsets with unique biological characteristics and refine the accuracy of overall survival (OS) prediction (Abstract #11545)
New CGP Biomarkers, Including Homologous Recombination Deficiency (HRD) Signature and Methyl Thioadenosine Phosphorylase (MTAP) Genomic Loss
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx) (Abstract #591)
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors (Abstract #3129)
Nature and distribution of methyl thioadenosine phosphorylase (MTAP) genomic loss in human tumors (Abstract #3067)
Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course (Abstract #1060)
Impact of Ancestry on the Genomic Alteration Landscape
Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC) (Abstract #4138)
Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes (Abstract #5614)
"Our data at this year’s ASCO (Free ASCO Whitepaper) annual meeting reflects Foundation Medicine’s progress in making genomic profiling indispensable to cancer care and research, particularly in lung, breast and prostate cancers where there is an increasing number of targeted therapies for health care providers to consider for these patients," says Mia Levy, MD, PhD, Chief Medical Officer at Foundation Medicine. "We are also excited to demonstrate our new RNA sequencing capabilities and spotlight the expanding utility of ctDNA to inform treatment decision making through a simple blood sample."
The following is a complete list of Foundation Medicine abstracts that will be presented. To access the abstracts being presented at ASCO (Free ASCO Whitepaper), please visit ASCO (Free ASCO Whitepaper).org/abstracts.
Follow Foundation Medicine on LinkedIn, X and Instagram for more updates from #ASCO24 and visit us in person at Booth #22031.
Abstract #
Title
Collaborator
Products
Posters
Abstract #3127
6/1/2024 9:00 AM-
12:00 PM
On the right TRACK: Providing comprehensive genomic profiling (CGP) and molecular tumor board (MTB) for patients (pts) with rare cancers
TargetCancer Foundation, UC San Diego Moores Cancer Center, University of California, San Diego, Medical College of Wisconsin (MCW) Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins Hospital, The University of Texas MD Anderson Cancer Center, Department of Pharmacy, Rutgers New Jersey Medical School, Medication Acquisition, Inc., Sarah Cannon Research Institute, University of Nebraska, WIN Consortium for Precision Medicine
FoundationOneCDx
FoundationOneLiquid CDx
Abstract #3129
6/1/2024 9:00 AM-
12:00 PM CDT
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors
Memorial Sloan Kettering Cancer Center
FoundationOneCDx
FoundationOneLiquid CDx
Abstract #4138
6/1/2024 1:30 PM-
4:30 PM CDT
Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC)
Yale Cancer Center, New York University Perlmutter Cancer Center
FoundationOneCDx
Flatiron Health-Foundation
Medicine Clinico-Genomic
Database (CGDB)
Abstract #TPS3644
6/1/2024 1:30 PM-
4:30 PM CDT
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO
University of Pisa, Italy
FoundationOneTracker
Abstract #11545
6/1/2024 1:30 PM-
4:30 PM CDT
New soft tissue sarcoma (STS) transcriptomic clusters to unveil STS subsets with unique biological characteristics and refine the accuracy of overall survival (OS) prediction
Universitario Lisboa Norte, Institute Portugues de Oncologia de Lisboa Francisco Gentil, Institute Superior Tecnico, Universidade de Lisboa, Institute de Medicina Molecular Joao Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, F. Hoffmann-La Roche AG, Institute Superior Tecnico (1ST), Universidade de Lisboa, Hospital CUF Descobertas
FoundationOneRNA for
research use
Abstract #3067
6/1/2024 9:00 AM-
12:00 PM CDT
Nature and distribution of methyl thioadenosine phosphorylase (MTAP) genomic loss in human tumors
San Raffaele Hospital and Scientific Institute, Italy
FoundationOne
FoundationOneCDx
Abstract #1060
6/2/2024 9:00 AM-
12:00 PM CDT
Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): co-occurrence and prevalence along treatment course
Emory University
FoundationOneCDx
FoundationOneLiquid CDx
Flatiron Health-Foundation
Medicine Clinico-Genomic
Database (CGDB)
Abstract #591
6/2/2024 9:00 AM-
12:00 PM CDT
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx)
Stanford University
FoundationOneCDx
Flatiron Health-Foundation
Medicine Clinico-Genomic
Database (CGDB)
Abstract #5056
6/2/2024 9:00 AM-
12:00 PM CDT
BRCA1/2 reversion mutations in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy
Cedars-Sinai Medical Center, Upstate University Medical Center, University of California – San Diego
FoundationOneLiquid CDx
Abstract #1042
6/2/2024 9:00 AM-
12:00 PM CDT
Utility of circulating tumor DNA (ctDNA) to inform treatment of patients with metastatic breast cancer
Johns Hopkins University School of Medicine, Vanderbilt University Medical Center, Allegheny Health Network, Weill Cornell Medicine and New York-Presbyterian Hospital
FoundationOneLiquid CDx
Abstract #5091
6/2/2024 9:00 AM-
12:00 PM CDT
Impact of alterations in tumor suppressor genes (TSG-alt) on survival outcomes in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) receiving androgen deprivation therapy (ADT) with androgen receptor pathway inhibition (ARPI) or docetaxel
Huntsman Cancer Institute, Masonic Cancer Center
Flatiron Health-Foundation
Medicine Clinico-Genomic
Database (CGDB)
Abstract #5085
6/2/2024 9:00 AM-
12:00 PM CDT
Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC)
Rogel Comprehensive Cancer Center, University of Michigan, Karmanos Cancer Institute, Wayne State University
FoundationOneLiquid CDx
Abstract #5020
6/2/2024 9:00 AM-
12:00 PM CDT
Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Peter MacCallum Cancer Centre, Department of Medical Oncology, Institut Gustave Roussy, University of Paris-Saclay, Pfizer Inc., National Cancer Center Hospital East, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, The Urology Center of Colorado, National Cancer Center, Tom Baker Cancer Centre, University of Calgary, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Huntsman Cancer Institute (NCI-CCC), University of Utah
FoundationOneLiquid CDx
FoundationOneMonitor for
Research Use
Abstract #3626
6/2/2024 9:00 AM-
12:00 PM CDT
Contrasting comprehensive genomic profiles of adenocarcinomas of the appendix in younger versus older patients
Upstate Medical University
FoundationOne
FoundationOneCDx
Abstract #4588
6/2/2024 9:00 AM-
12:00 PM CDT
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study
Upstate Medical University, University of California – Los Angeles, University of Washington, Huntsman Cancer Center, Moffitt Cancer Center, MD Anderson Cancer Center, Cleveland Clinic, San Rafael University
FoundationOne
FoundationOneCDx
Abstract #8032
6/2/2024 9:00 AM-
12:00 PM CDT
Retrospective analysis of change in frequency of STK11 mutation in lung adenocarcinomas over a 10-year period
Upstate Medical University
FoundationOne
FoundationOneCDx
Abstract #1092
6/2/2024 9:00 AM-
12:00 PM CDT
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)
Yale University
FoundationOne
FoundationOneCDx
Abstract #11575
6/2/2024 9:00 AM-
12:00 PM CDT
Intimal sarcomas (ISarc) of the cardiac chambers (CC) of the heart and great vessels (GV): A comprehensive genomic profiling (CGP) study
Upstate Medical University
FoundationOne
FoundationOneCDx
Abstract #6036
6/2/2024 9:00 AM-
12:00 PM CDT
Clinical, molecular, and immunologic profiling of brain metastases (BM) in head and neck squamous cell carcinoma (HNSCC)
Dana-Farber Cancer Institute, University of California – San Diego, Phase Genomics
Abstract #5614
6/3/2024 9:00 AM-
12:00 PM CDT
Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes
University of Colorado Health, Mount Sinai
FoundationOneCDx
Abstract #8068
6/3/2024 1:30 PM-
4:30 PM CDT
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early-stage lung cancer (LEADER) screening trial
Baylor College of Medicine, Harvard University, University of Michigan, University of Missouri, University of Washington, University of California – Los Angeles, University of Colorado, Memorial Sloan Kettering
FoundationOneCDx
FoundationOneLiquid CDx
Abstract #8532
6/3/2024 1:30 PM-
4:30 PM CDT
Molecular profiling across histologies in lung cancer: Time to change WHO nomenclature?
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Papardo Hospital, Roche Sequencing Solutions
FoundationOneCDx